861 related articles for article (PubMed ID: 11714817)
41. Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo.
Erdmann AA; Gao ZG; Jung U; Foley J; Borenstein T; Jacobson KA; Fowler DH
Blood; 2005 Jun; 105(12):4707-14. PubMed ID: 15746085
[TBL] [Abstract][Full Text] [Related]
42. Disparate cytotoxic activity of nickel-specific CD8+ and CD4+ T cell subsets against keratinocytes.
Traidl C; Sebastiani S; Albanesi C; Merk HF; Puddu P; Girolomoni G; Cavani A
J Immunol; 2000 Sep; 165(6):3058-64. PubMed ID: 10975816
[TBL] [Abstract][Full Text] [Related]
43. Migration kinetics and final destination of type 1 and type 2 CD8 effector cells predict protection against pulmonary virus infection.
Cerwenka A; Morgan TM; Harmsen AG; Dutton RW
J Exp Med; 1999 Jan; 189(2):423-34. PubMed ID: 9892624
[TBL] [Abstract][Full Text] [Related]
44. CD8Tc1 and Tc2 cells secrete distinct cytokine patterns in vitro and in vivo but induce similar inflammatory reactions.
Li L; Sad S; Kägi D; Mosmann TR
J Immunol; 1997 May; 158(9):4152-61. PubMed ID: 9126975
[TBL] [Abstract][Full Text] [Related]
45. Immunobiology of allograft rejection in the absence of IFN-gamma: CD8+ effector cells develop independently of CD4+ cells and CD40-CD40 ligand interactions.
Bishop DK; Chan Wood S; Eichwald EJ; Orosz CG
J Immunol; 2001 Mar; 166(5):3248-55. PubMed ID: 11207279
[TBL] [Abstract][Full Text] [Related]
46. Partially TAP-independent protection against Listeria monocytogenes by H2-M3-restricted CD8+ T cells.
Rolph MS; Kaufmann SH
J Immunol; 2000 Oct; 165(8):4575-80. PubMed ID: 11035099
[TBL] [Abstract][Full Text] [Related]
47. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells.
Ribas A; Wargo JA; Comin-Anduix B; Sanetti S; Schumacher LY; McLean C; Dissette VB; Glaspy JA; McBride WH; Butterfield LH; Economou JS
J Immunol; 2004 Apr; 172(8):4762-9. PubMed ID: 15067052
[TBL] [Abstract][Full Text] [Related]
48. Vaccination with tumor peptide in CpG adjuvant protects via IFN-gamma-dependent CD4 cell immunity.
Stern BV; Boehm BO; Tary-Lehmann M
J Immunol; 2002 Jun; 168(12):6099-105. PubMed ID: 12055220
[TBL] [Abstract][Full Text] [Related]
49. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
Xie Y; Bai O; Zhang H; Li W; Xiang J
Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
[TBL] [Abstract][Full Text] [Related]
50. Self-reactive T cell receptor-reactive CD8+ T cells inhibit T cell lymphoma growth in vivo.
Gonthier M; Llobera R; Arnaud J; Rubin B
J Immunol; 2004 Dec; 173(11):7062-9. PubMed ID: 15557204
[TBL] [Abstract][Full Text] [Related]
51. Immune deviation of 2C transgenic intraepithelial lymphocytes in antigen-bearing hosts.
Guehler SR; Bluestone JA; Barrett TA
J Exp Med; 1996 Aug; 184(2):493-503. PubMed ID: 8760803
[TBL] [Abstract][Full Text] [Related]
52. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
53. The phenotype of type 1 and type 2 CD8+ T cells activated in vitro is affected by culture conditions and correlates with effector activity.
Kemp RA; Bäckström BT; Ronchese F
Immunology; 2005 Jul; 115(3):315-24. PubMed ID: 15946249
[TBL] [Abstract][Full Text] [Related]
54. Type 2 cytotoxic T lymphocytes modulate the activity of dendritic cells toward type 2 immune responses.
Iezzi G; Boni A; Degl'Innocenti E; Grioni M; Bertilaccio MT; Bellone M
J Immunol; 2006 Aug; 177(4):2131-7. PubMed ID: 16887972
[TBL] [Abstract][Full Text] [Related]
55. Can the low-avidity self-specific T cell repertoire be exploited for tumor rejection?
Cordaro TA; de Visser KE; Tirion FH; Schumacher TN; Kruisbeek AM
J Immunol; 2002 Jan; 168(2):651-60. PubMed ID: 11777958
[TBL] [Abstract][Full Text] [Related]
56. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
[TBL] [Abstract][Full Text] [Related]
57. Production of interferon-gamma by influenza hemagglutinin-specific CD8 effector T cells influences the development of pulmonary immunopathology.
Wiley JA; Cerwenka A; Harkema JR; Dutton RW; Harmsen AG
Am J Pathol; 2001 Jan; 158(1):119-30. PubMed ID: 11141485
[TBL] [Abstract][Full Text] [Related]
58. Type 2 immune deviation has differential effects on alloreactive CD4+ and CD8+ T cells.
Matesic D; Valujskikh A; Pearlman E; Higgins AW; Gilliam AC; Heeger PS
J Immunol; 1998 Nov; 161(10):5236-44. PubMed ID: 9820495
[TBL] [Abstract][Full Text] [Related]
59. A nonclassical MHC class I molecule restricts CTL-mediated rejection of a syngeneic melanoma tumor.
Chiang EY; Stroynowski I
J Immunol; 2004 Oct; 173(7):4394-401. PubMed ID: 15383569
[TBL] [Abstract][Full Text] [Related]
60. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
Cao X; Zhang W; He L; Xie Z; Ma S; Tao Q; Yu Y; Hamada H; Wang J
J Immunol; 1998 Dec; 161(11):6238-44. PubMed ID: 9834111
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
